Compare Crispr Therapeutics AG (CRSP) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs OneSpan Inc — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while OneSpan Inc trades at $15.19 (market cap $574.63M). The key difference: Crispr Therapeutics AG is far larger — about 8.6× OneSpan Inc's market cap, and OneSpan Inc pays a 3.35% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | OSPN | |
|---|---|---|
Market Cap | $4.97B | $574.63M |
Sector | Health | Technology |
52-Week High | $76.78 | $16.32 |
52-Week Low | $44.34 | $10.15 |
Enterprise Value | $3.32B | $532.83M |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
OneSpan (OSPN) trades at $15.09, down 0.53% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company demonstrates strong profitability with a net income margin of 28.47% and has beaten earnings estimates for the last three quarters. Recent news highlights investor attention and the upcoming Q2 2026 earnings release on August 4, 2026.
The outlook remains positive given consistent earnings beats and a 66.7% analyst buy rating, though the consensus price target of $13.50 suggests limited upside. Risks include negative net cash flow trends and potential margin compression, but strong ROE of 27.81% supports shareholder value. The stock presents a value opportunity with a P/E of 8.56, but investors should monitor execution against future guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
